Diagnosis of drug-resistant TB and provision of second-line TB treatment in India: some ethical considerations.
Indian J Med Ethics
;
2013 Apr-Jun;10 (2): 110-114
Artículo
en Inglés
| IMSEAR
| ID: sea-181131
ABSTRACT
Background:
The GeneXpert® MTB/RIF (hereinafter Xpert) test has demonstrated sensitive detection of tuberculosis (TB) and Rifampicin resistance directly from untreated sputum in less than two hours. India is currently drafting the third phase of its Revised National Tuberculosis Control Programme (RNTCP). This process provides the country’s health authorities with an ideal opportunity to revolutionise TB management in the country. The RNTCP is currently conducting a multi–site demonstration study to gather operational evidence to scale up the Xperttest under Indian programme conditions.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Tipo de estudio:
Estudio diagnóstico
Idioma:
Inglés
Revista:
Indian J Med Ethics
Asunto de la revista:
Ethics
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS